WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Wednesday, October 29, 2014

Understanding and Managing PD-Related Shame and Embarrassment


Friday October 17, 2014
Those of us living with PD often experience distressing shame and embarrassment secondary to some of our PD symptoms. When eating in public, for example, hand tremors can cause us to spill food all over the dining table and ourselves. The same tremors plus slowness of movement, have us struggle getting money or credit cards out of our wallets while the cashier, and customers waiting in line, show clear signs of impatience. Excessive salivation can result in drooling. Poor balance makes us walk unsteadily, as if under the influence of alcohol or drugs. The list is not exhaustive.
A good friend of mine who has struggled with PD for the past three years put it this way:
I am embarrassed by my hand shaking, I don’t like the feeling of having little control over such an expressive part of my body. Unfortunately, trying hard to make it stop only seems to make it worse…
 [I feel embarrassment] when gesturing during personal conversations I notice the eyes of my conversational companion move to my tremoring hand…
Embarrassment and shame are powerful emotions that can seriously disrupt our sense of well-being. They heighten our anxiety. They place us at risk for greater distress in the form of social and emotional isolation, and/or psychiatric disorders such as phobias and depression.
We cope with shame and embarrassment in different ways. Typically we keep ourselves in a state of constant alertness wherein we scan the environment for potentially shame-inducing situations and when we spot them we proceed to avoid them. If avoidance is not possible, we anticipate possible obstacles and formulate a solution. We hide symptoms. We dissimulate.
Shame, while frequently encountered by PWP’s, is infrequently discussed. There is irony at play. For many PWPs, it is embarrassing to talk about embarrassments.
The Psychology behind Shame
Viewed from the lens of psychology, cognitively, shame is an emotion that originates from a set of beliefs, namely that one’s body and/or mind are flawed in some significant way; that the presumed defect or stigmata must be kept hidden, secret, away from the scrutiny of others; that to do otherwise exposes the self to public ridicule, scorn or rejection. We fear exposure.
When shame is experienced in public, and it is of mild to moderate intensity, it is known as embarrassment. We feel observed and reproached by others. We blush, we cover our faces, we wish to escape the situation. In its severe form, shame becomes humiliation, and then we wish we had never existed at all.
It appears that the frequency and intensity of felt shame and embarrassment vary; there are individual differences. PWP’s with a premorbid history of self-consciousness, shyness, introversion, interpersonal sensitivity, or socially avoidant behaviors are presumed to be more vulnerable than their extroverted, socially outgoing counterparts.
But living in fear and defending ourselves trough avoidances needs not be our fate.
Coping Effectively with Shame & Embarrassment
A more effective way to cope is to confront the fears head on, with assistance from a psychotherapist trained in Cognitive-Behavioral Therapy (CBT). One helpful technique, among many others, is that of behavioral exposure to the paralyzing fear. The idea is that the client engages in an activity that brings on the fear of embarrassment and in doing so, and working through it, learns that the situation is not devastating. When combined with other CBT techniques, such as cognitive restructuring, thought stopping, disputing the inner critic, relaxation techniques, mindfulness training, such forms of behavioral exposure can result in lasting changes. Practical advice: Discuss your fears with your health team and obtain a referral for CBT with a trained therapist.
But psychotherapy is not for everyone.  Some PWP’s might  prefer to enlist the help of a life coach  who will assist the PWP with the formulation and implementation of  behavioral goals and objectives that are antidotes to fear—like courage, for example. Practical advice: Access a reputable website on coaching and positive psychology, such as www.positiveacorn.com
It might also be the case that the PWP prefers self-management or self-help efforts. This can be effective too, provided that the recommended interventions are evidence based.

https://www.nwpf.org/stay-informed/blog/2014/10/shame-embarrassment/

Intel turns to wearables, Big Data to fight Parkinson's


Credit: Thinkstock

Medical researchers today have only a rudimentary understanding of how Parkinson's disease progresses in patients. In collaboration with the Michael J. Fox Foundation, Intel is helping researchers use wearable devices, the Internet of Things and big data technologies to collect and analyze patient data.



For the past year, Intel and Parkinson's disease researchers have been conducting trials of a revolutionary new method for measuring the progress of the neurodegenerative brain disease in patients using wearables, the Internet of Things (IoT) and big data analytics. Just a few weeks ago, the project moved out of specific clinical trials, and researchers have begun outfitting patients with devices to begin gathering data.
"We started with a few trials of about 50 patients each, just to make sure the technology was working and the analytics were tuned. We've now expanded that to a much broader base," says Ron Kasabian, vice president and general manager of Big Data Solutions at Intel. "The researchers don't even know what normal looks like. What we're trying to do is to help them and us get lots and lots of data to understand what does normal look like."
[ More: Big Data Analytics Use Cases in Healthcare, Part 1 and Part 2 ]
He notes that by the end of next year, the project hopes to have 10,000 patients opt in for monitoring. There are about 1 million people in the U.S. with Parkinson's disease and another 5 million globally.

Former Intel CEO, Cancer Survivor Andy Grove Hit Parkinson's Head On

Intel's road to Parkinson's research began with Intel co-founder and former CEO Andy Grove, who was diagnosed with the disease in 2000, not long after stepping down from his position as Intel's CEO. Grove is a fighter. He survived a Fascist dictatorship, German military occupation and a variety of repressive Communist regimes before emigrating from his native Hungary in 1956. When he arrived in the United States, he worked as a busboy. A few years later, he held a Ph.D in chemical engineering from the University of California, Berkeley. Grove would go on to help found Intel and then, as its leader, transform it from a provider of memory chips to the largest maker of microprocessors in the world.
In 1995, Grove was diagnosed with prostate cancer. With an engineer's rigor, he set about researching his treatment options and the state of medical research on the disease. Only a few years later, he took a similar approach to Parkinson's.
Parkinson's disease is a neurodegenerative brain disease in which the dopamine-generating cells in a particular region of the midbrain begin to die, progressively causing symptoms such as shaking, muscle rigidity, slow movement and difficulty walking. It also causes sleep problems and cognitive and behavioral problems, commonly leading to dementia in advanced stages.
Researchers understand very little about the progression of the disease, Kasabian says. "We can't find any commonality."
A big part of the problem, he says, is the test neurologists currently use to track the progression of the disease in patients. On a regular schedule, they conduct the Uniform Parkinson's Disease Rating Scale. In the course of 15 minutes, a doctor judges how well the patient speaks, moves and walks. The test is highly subjective, Kasabian says, as the severity of the symptoms of a Parkinson's disease patient can vary hour to hour.

Nearly 200 years after Dr. James Parkinson first described the disease, doctors "are still subjectively measuring Parkinson's disease," says Todd Sherer, CEO of The Michael J. Fox Foundation, which is collaborating with Intel on the project.

More Rigorous Monitoring of Parkinson's Patients

Grove wanted a better, more rigorous way of measuring what was happening to his body and millions of other patients like him. About 15 months ago, he asked Intel for help in doing that, Kasabian says, noting that it took the company about four months to understand the different options and how to start.
Together with researchers, Intel recognized that the problem was getting objective data, and lots of it. The solution was surprisingly simple: A wearable with an accelerometer — the same accelerometer that can be found in every smartphone, smartwatch or other wearable device.
For the clinical trials, Intel and the researchers opted for a simple, off-the-shelf smartwatch, but Kasabian notes it could be a pendant or any other type of wearable with an accelerometer. The unobtrusive device measures slowness of movement, tremor and sleep quality 24 hours a day, seven days a week. The device takes more than 300 observations per second from each patient — about 1 GB of data per patient per day.
Within the next year, researchers hope to be able to capture EKG, blood pressure and, especially, heart rate data. "They don't know whether there's a correlation between heart rate and disease progression," Kasabian says. Researchers also want to see the effect of medication in real-time.
To analyze all that data, Intel developed a big data analytics platform built on the Cloudera CDH distribution of Apache Hadoop. It deployed the platform on cloud infrastructure. Intel developed an analytics application to process and detect real-time changes. The idea is to create a baseline and then detect anomalies and changes in sensor and other data to provide researchers with a way to objectively measure disease progression.
"Given where they're coming from, a simple time-series analysis is incredibly insightful for them. They were thrilled," Kasabian says. "Working with the researchers, we can look at specific patterns in those time series. Eventually, the system will identify certain patients where it is progressing at an accelerated rate over normal, but we have to collect a lot of data first to understand what normal is."
"Data science and wearable computing hold the potential to transform our ability to capture and objectively measure patients' actual experience of disease, with unprecedented implications for Parkinson's drug development, diagnosis and treatment," adds Sherer: 
This story, "Intel turns to wearables, Big Data to fight Parkinson's" was originally published by CIO.

http://www.topix.com/health/parkinsons-disease/2014/10/intel-turns-to-wearables-big-data-to-fight-parkinsons

Tuesday, October 28, 2014

Change in the way you walk could be key to Parkinson's diagnosis

Changes in the way people walk could give insight into Parkinson's disease Photo: ALAMY

Changes in the way people walk could be an early sign of cognitive decline in Parkinson's disease, according to a new study.
Researchers claim to have discovered a definitive link between a change in someone's gait and a decline in their cognitive function.
More than 120 people with Parkinson's took part in the study, where they had to walk for two minutes in the lab and their stride pattern was then analysed.
Changes in gait, such as taking slower, shorter steps, irregular walking patterns or a swaying motion, were found to be related to cognitive decline.
It is hoped the findings could help doctors spot the risk of dementia and future cognitive impairment in Parkinson’s patients, providing an earlier indicator than current tests on the brain.
Although the disease cannot be cured, early diagnosis can assist with the management of symptoms.
Some degree of cognitive impairment affects most people with Parkinson’s disease. The same brain changes that lead to motor symptoms can also result in slowness in memory and thinking. Research has also found that many people who have Parkinson's go on to develop a mild form of dementia.
Lynn Rochester, professor of human movement science at Newcastle University and lead author of the paper, said: "The relationship between gait and cognition has never been established this early on and in such a large group of Parkinson's before.
"In the future walking patterns may be a useful early warning system to help identify dementia risk in Parkinson's.
"Subtle changes in someone's walking pattern, for example slowing down of steps, and increased sway from side to side are related to cognitive function even before changes are seen in cognitive tests.
"Ongoing work will confirm if it is possible to predict future cognitive decline and dementia risk. However this early work shows great promise.
"If we can use this and test people who may at risk, then we could pick up the early signs and begin treatment and advice."
Prof Rochester said it had been known for several years that there was a link between gait disturbance and dementia in older adults, but until now the relationship had not been clear in Parkinson's.

http://health.einnews.com/article/230448801/oOhGI66DR1m4Dg5t?n=2&code=ga_qGBxHZ2aVYO4P

Monday, October 27, 2014

Klotho, The Genetic Spinner of Aging Destiny



Indeed, we are all destined to age, but some age better than others. Some age faster and some slower. A gene called Klotho appears to be the cause.  Klotho seems a rather strange name for a gene, but it comes from the name of one of the triad of Greek Goddesses known as the Fates, those independent controllers of destiny, to whom even the gods must submit.  The genetic Klotho was accidentally discovered as the missing gene that caused premature aging in a group of transgenic mutated laboratory mice. Many studies implicated of the lack of Klotho in disease processes, including kidney disease.  Newer studies have shown the protective qualities the presence of Klotho provides on reducing oxidative stress, improving blood pressure and preserving the retina in the eye.  Klotho can slow aging and prevent loss of mental abilities.  Now the newest study shows additional Klotho promotes neuroprotection in the brain.

A team of researchers for Boston University has recently published their study findings in the Journal of Biological Chemistry showing the neuroprotective effect of Klotho against Alzheimer’s disease.  They grew nerve cells in petri dishes in the laboratory.  Klotho was added to some of the dishes.  When amyloid, like that which is found to accumulate in the neurons of Alzheimer’s disease, was added to all the dishes, the ones with the added Klotho showed a much higher survival rate of nerve cells than the untreated dishes.  Carmela Abraham, Ph.D.is the principal investigator of this study and a professor of biochemistry and pharmacology at Boston University Medical Center.  She says “We now have evidence that if more Klotho is present in the brain, it will protect the neurons from the oxidative stress induced by amyloid and glutamate.  Finding a neuroprotective agent that will protect nerve cells from amyloid that accumulates as a function of age in the brain is novel and of major importance.”

However, it is not possible to introduce Klotho directly as a pill or an injection as it is a large molecule that cannot cross the blood-brain barrier.  A compound of smaller molecules that can cross the blood-brain barrier and increase the levels of Klotho in the brain is presently under development.  Dr. Abraham believes that “increasing Klotho levels with such compounds would improve the outcome for Alzheimer’s patients, and if started early enough would prevent further deterioration. This potential treatment has implications for other neurodegenerative disease such as PARKINSON’S, Huntington’s, ALS and brain trauma, as well.”

E. Zeldich, C.-D. Chen, T. A. Colvin, E. A. Bove-Fenderson, J. Liang, T. B. Tucker Zhou, D. A. Harris, C. R. Abraham. The Neuroprotective Effect of Klotho is Mediated via Regulation of Members of the Redox SystemJournal of Biological Chemistry, 2014; DOI: 10.1074/jbc.M114.567321

Review by Marcia McCall
http://parkinsonhope.org/klotho-genetic-spinner-aging-destiny/


Sunday, October 26, 2014

Medicine Report Calls for Sweeping Reforms to End-of-Life Care

Neurology Today:
doi: 10.1097/01.NT.0000456272.80245.3f


A new report by the Institute of Medicine has found that the quality of care patients wish to receive at the end of life rarely accords with the care they do receive. The report proposes a reformed model of end-of-life care that is more “person-centered, family-oriented, and evidence-based.”
When patients with terminal illnesses — neurologic or otherwise — come to the end of life, the care they receive should reflect their preferences, values, and goals, articulated over a series of thoughtful and comprehensive conversations held with their physicians, caregivers, and family members. But the quality of care patients wish to receive at the end of life is rarely commensurate with the care they do receive, a new report from the Institute of Medicine (IOM) found.
Authored by the IOM's 21-member Committee on Approaching Death: Addressing Key End of Life Issues, the 507-page report, titled “Dying in America: Improving Quality and Honoring Individual Preferences Near the End of Life” and published Sept. 17 by The National Academies Press, called for sweeping changes to the way end-of-life care is taught, funded, and administered.
At the heart of the IOM report is the finding that patients at the end of life generally prefer, and are much better served by, treatment focused on managing pain, improving quality of life, and keeping the patient within their own home, as opposed to costly in-hospital interventions. This includes palliative and hospice care, which is not well understood by patients, or even by certain healthcare providers, the report noted.
The report sketches out a detailed picture of end-of-life care in the United States as it exists today, and advocates for more comprehensive standards governing discussions of end-of-life care in medical education, physician-patient interactions, and public awareness campaigns. It also emphasizes the need for Medicare and private insurers to fund end-of-life care in a way that incentivizes palliative and hospice care as opposed to acute in-hospital interventions.
Across five overarching recommendations, the report outlines a plan of action by which end-of-life care can become more “person-centered, family-oriented, and evidence-based” — care of the highest quality [See sidebar, “IOM Recommendations for End-of-Life Care”].
Neurologists and palliative care specialists not involved with the IOM report who spoke with Neurology Today felt it provided an accurate snapshot of the current state of end-of-life care in the US, and that it addressed some key challenges to providing high-quality care at the end of life. They also hoped the report would serve as a wake-up call for physicians, policymakers, and healthcare advocates, prompting a necessary overhaul to end-of-life care.
Back to Top | Article Outline

RECOMMENDATIONS

The IOM committee proposed a model for advance care planning that requires an ongoing dialogue between patient and physician — one that could begin as early as when a person turns 18 or receives their driver's license — about values and goals for care at the end of life. As a patient ages and their medical circumstances change, turning those values and goals into clear statements embodied in flexible written documents and medical orders is paramount, the authors wrote.
These advance care planning discussions should include not only the physician and the patient, but also any caregivers, social workers, nurses, family members, or other loved ones involved in caring for the patient, the report added. If a patient then becomes unable to express their care preferences at the end of life — as is often the case for those with neurodegenerative illnesses — a surrogate decision-maker will be better equipped to act as an informed advocate for the patient.
The report also advised that Medicare, as well as private insurers, should reimburse physicians for these end-of-life care conversations, and called for an end to the “perverse financial incentives” that encourage hospitals and clinicians to order life-saving care for severely old and infirm patients, who often prefer less invasive palliative care.

“While hospital and intensive care undoubtedly saves the lives of a great many otherwise healthy people, it is not necessarily useful — and is, on the contrary, harmful — for people with advanced and irreversible chronic illnesses,” the authors wrote. “Yet it is hospital care, not community- or home-based care, that consumes the largest share of Medicare spending for patients in the final phase of life.
“Incentives under fee-for-service Medicare result in more use of services (hospital days, intensive care, emergency care), more transitions among care settings that are a burden on patients, and late enrollment in hospice, all of which jeopardize the quality of end-of-life care and add to its costs,” they added.
Alternatives to emergency and in-hospital services, such as home emergency and health services and caregiver support, should be available to patients around the clock, in order to reduce the number of unnecessary 911 calls and emergency room visits a terminal patient in distress might make, they said.
The report also recommended improving medical education, training, and certification for clinicians who care for seriously ill patients, advocating for well-developed “standards for clinician-patient communication and advance care planning that are measurable, actionable, and evidence based.” The authors also emphasized the need for collaboration between primary physicians and specialists, nursing staff, caregivers, and other healthcare providers, in all matters relating to end-of-life care.
Ultimately, these sweeping reforms stand to lower national health care costs by reducing expensive and unwanted acute care services, such as 911 calls, emergency room visits, and hospitalizations, for patients at the end of life, the report argued.
“Because most people who participate in effective advance care planning choose maximizing independence and quality of life over living longer, advance care planning can potentially save health care costs associated with unnecessary and unwanted interventions,” the authors wrote. “The committee believes these savings would free up funding for relevant supporting services — for example, caregiver training, nutrition services, and home safety modifications — that would ensure a better quality of life for people near the end of life and protect and support their families.”
Back to Top | Article Outline

RESPONSE TO THE REPORT

Independent experts involved in caring for patients at the end of life applauded the paper for its broad scope and its attention to key issues plaguing end-of-life care, including the need for an ongoing discussion between patient and physician about end-of-life care preferences; for better education and awareness of palliative and hospice care options; and for restructuring Medicare in order to de-incentivize unnecessary medical interventions for patients at the end of life.
“The contrast between the manner in which Americans are approaching their end of life and the type of care they're asking for is, almost any way you look at it, inappropriate,” Adam Marks, MD, an assistant professor of hospice and palliative medicine at the University of Michigan Health Center and associate director of the adult Palliative and Supportive Care Clinic at the East Ann Arbor Health and Geriatrics Center in Ann Arbor, MI, told Neurology Today.
Dr. Marks cited data, which is also mentioned in the IOM report, showing that those with advanced illness who pursue palliative and comfort-centered care at the end of life tend to live longer than those who seek aggressive medical interventions. Palliative care specialists “want our patients to get all of the care that is going to benefit them, but none of the care that isn't,” he said.
Stephan A. Mayer, MD, a neurointensivist at Mount Sinai Hospital and director of the Institute for Critical Care Medicine at the Icahn School of Medicine at Mount Sinai in New York, NY, agreed in particular with the report's suggestion that perverse financial incentives motivate a standard of end-of-life care that goes against a patient's best interests.
“I've seen low-quality end-of-life care, and it's horrible,” Dr. Mayer said. “Large numbers of frail elderly are effectively warehoused, they get tracheostomies and feeding tubes, they're bed-bound, and doctors come by for their brief visits and bill Medicare. The doctors are not having discussions about what this person would really want, and they're not even offering comfort as an option.”
The recommendation that physicians could initiate advance care planning conversations as early as when a patient turns 18 also elicited positive comments from experts, with a few caveats. All agreed that drawing attention to end-of-life care early in life may serve to normalize and de-stigmatize the conversation, and that involving family members and caregivers in advance care planning discussions could be extremely helpful.
However, Dr. Marks cautioned against getting into the specifics of advance care planning with a young patient who is not terminally ill. “I don't want to see detailed advance directives being filled out by a patient at age 18, because they will be almost meaningless,” he said. But, he added, “goals of care isn't a destination, it's a process. I like the idea of introducing those concepts at 18.”
Allison R. Gray, MD, a neurologist in private practice in Boston, MA, added that the report's emphasis on including family members and caregivers in advance care planning discussion was significant because it may cut down on instances where surrogate decision-makers do not know how to act in the best interests of patients who become too incapacitated to express themselves.
“Having health care providers work with the families and involve them in the conversation [would be helpful], because hopefully when the family has heard ‘This is what I want’ so many times, they can't ignore it,” she said. Dr. Gray previously collaborated on the Neurology Goals of Care Initiative at Massachusetts General Hospital, an ongoing program tasked with improving end-of-life care for patients with neurological illness.
“Even with all the planning in the world, you're never going to be able to completely account for the specific circumstances, the nuances and the gray areas, when it's really crunch time,” Dr. Mayer added. “For a lot of the people that have to make these [end-of-life] decisions, the responsibility is thrust upon them. We need to start focusing more on the surrogate decision-makers, the role of the family in actively dealing with the crisis situation.
“It's always a three-way conversation” between the physician, the patient, and the family member or surrogate decision-maker, he said.
Back to Top | Article Outline

BETTER COMMUNICATION

One of the best ways to reform and re-frame the public discourse around end-of-life care is to shift the conversation from an emphasis on death and dying to an emphasis on quality of life, Dr. Marks said — a concept that was not discussed as thoroughly in the IOM report.
“The conversation continues to be about death and dying, and patients and doctors aren't too keen to have that conversation,” Dr. Marks said. “But when we talk about palliative care, we're not trying to say that palliative care is going to help you die better, we're saying it is going to help you live better.”
“Terms like ‘pull the plug’ and ‘withdraw care’ make my skin crawl,” Dr. Gray said. “I prefer the term ‘changing the goals of care.’ My hope is that changing the language we use will make people less nervous that we're trying to do less [to care for the patient]. You're actually doing a lot more to help the patient, you're just doing it in a different way.”
By framing the conversation in terms of quality of life, they said, patients may be better equipped to understand and consider the benefits of palliative and hospice care.
More education about palliative and hospice care, as well as teaching physicians how to best frame conversations about end-of-life care, will be part of the solution, Dr. Gray said. “Our ability as healthcare providers and physicians to talk to patients and their families in a compassionate and knowledgeable way about end-of-life issues is so lacking. The fact that the report is putting a spotlight on the lack of education is important, because it needs to be addressed.”
There is a need, several experts said, to better define the boundaries of palliative care in the field and to train neurologists to recognize those standards and to know when it is appropriate to refer patients to specialists in palliative care in the toughest situations.
A multidisciplinary approach, with frequent communication between physicians, palliative care specialists, nurses, and other health care providers, will ultimately lead to a higher standard of care for the patient, said Lynne P. Taylor, MD, FAAN, a neuro-oncologist at the Virginia Mason Hospital and Seattle Medical Center in Seattle, WA.
“For instance, if you're a neuro-critical care physician and you're taking care of a stroke patient, you need to focus on the ventilator settings and whether the patient is going to recover,” she said. “It can be very helpful to have a colleague who is palliative care-based to take some of that burden off you, to have conversations with the family. Because the physician and the family may share a fixed delusion that every [intervention] is going to work, and you need somebody at arm's length to say, ‘Hold on a minute, let's go back to the patient's goals and preferences. Is this really consistent with what the patient would have wanted?’”


CHALLENGES AHEAD

Changing public and physician attitudes toward palliative and hospice care and providing medical education that trains physicians to have more compassionate, comprehensive conversations about end-of-life care with their patients will take time, said James L. Bernat, MD, FAAN, a professor of neurology and medicine at Dartmouth-Hitchcock Medical Center in Lebanon, NH.
“But attitudes are already changing,” he said. “Nearly every medical school now has some palliative care education, and it's part of postgraduate training and residency programs, too. We have palliative care faculty in essentially every academic medical center, and in most teaching hospitals. It's a huge social change that's occurred over the last 30 years or so. I think this process is well underway.”
However, the report's financial recommendations — those that would retool Medicare's reimbursement structure, de-emphasizing acute care at the end of life in favor of home health services — will require congressional action. And the US Congress is just as ideologically fragmented as it was in 2009, when a provision that would have reimbursed physicians for having end-of-life care discussions was removed from the Affordable Care Act over a public misconception that the bill would lead to “death panels,” Dr. Bernat pointed out.
“That reasonable, simple, important provision was left out of the Affordable Care Act because of demagoguery and fear-mongering. The ‘death panel’ myth was totally unfair and wrong — wrong not just morally, but factually — yet it took off and it poisoned the atmosphere to such an extent that even mentioning an end-of-life discussion became a barrier to having a politician vote in favor of the Affordable Care Act.”
All were optimistic that the report would continue to push end-of-life care in the right direction, however. “Change is incremental, and I don't think anyone is expecting us to burn the health care system to the ground and build it back up overnight,” Dr. Marks said. “But I think [the report] is an exciting opportunity to change the conversation.”
Neurology Today:
doi: 10.1097/01.NT.0000456272.80245.3f
Features




New Study Urges Stronger Warning for Parkinson’s Medications Tied to Impulsive Behaviors

FoxFeed Blog






Posted by  Rachel Dolhun, MD, October 24, 2014
New data supports more substantial warnings for dopamine agonists after confirming the strong association between these drugs and impulse control disorders (ICDs)— syndromes of compulsive gambling, hypersexuality and excessive shopping, to name a few.
This relationship has been known for many years but clinicians may have failed to grasp its magnitude and possible implications. A U.S. Food and Drug Administration (FDA) “black box” warning — a strong caution indicating a potentially serious medication side effect — would undoubtedly grab the attention of practitioners and change prescribing habits.
“The medical community does not appreciate how common these problems are and how serious they may be” says Howard D. Weiss, MD, director of the Parkinson’s Disease and Movement Disorder Programs at the LifeBridge Health Brain & Spine Institute in Baltimore. Dr. Weiss offered a commentary on the study.

Many Agonists Prescribed Despite Impulse Disorder Connection
Thomas Moore, AB, of the Institute for Safe Medicine Practices, and colleagues from Harvard Medical School and The University of Ottawa searched 10 years’ worth of submissions to the FDA Adverse Event Reporting System for reports of ICDs and correlated them with prescription medications.
Their findings, published in JAMA Internal Medicine, showed a significantly higher proportion of impulse control disorders with dopamine agonists as compared to other drugs. The majority of these agonists were prescribed for Parkinson’s disease but they also treat restless legs syndrome and hyperprolactinemia (a hormonal disorder). Pramipexole (Mirapex) and ropinirole (Requip) had the highest associations.  
Agonists bind to dopamine receptors in the brain, mimicking the chemical’s effect in regulating movement, risk-taking and reward-seeking. Pramipexole, ropinirole, and rotigotine (Neupro) are widely used to delay initiation of levodopa or lessen motor fluctuations. Apomorphine (Apokyn) is another dopamine agonist used as a rescue therapy for sudden “off” periods.
Impulse Disorders Can Gravely Impact Quality of Life
Impulse control disorders can take many forms — those mentioned earlier and also excessive eating, pathological hobbyism and taking higher than prescribed amounts of medication. The outcomes can range from a mere nuisance to disastrous consequences for family and social relationships, finances and careers. Dr. Weiss says he has personally witnessed people lose their homes because of bankruptcy related to gambling, divorce due to sexual misadventures, and seek hospitalization for depression stemming from impulsive actions.
No one is immune, but certain populations — younger males and anyone with a history of mood problems, obsessive-compulsive disorder, or prior drug or alcohol abuse — are at higher risk for these complications. People on dopamine agonists and their families need to be vigilant for odd behaviors. Clinicians must inquire specifically about buying lottery tickets and new interest in pornography rather than simply asking about general “side effects.” These conversations can be uncomfortable but are crucial to patient well-being.
Dr. Weiss encourages the medical field to accept that dopamine agonists are not necessarily safer or better than other medications. More than 2 million outpatient prescriptions for these drugs were dispensed in the United States in a single quarter in 2012. In their commentary, Dr. Weiss and his coauthor Gregory M. Pontone, MD, of Johns Hopkins University School of Medicine argue we have “overestimated the benefit and underestimated the risks associated with the use of dopamine receptor agonist drugs in patients with Parkinson’s disease.”
Bottom Line
  • For people taking these medications, this knowledge should increase awareness of behaviors and attitudes. Dopamine agonists are effective in many people and not everyone will experience side effects. Any change to medications should of course be discussed with the prescriber.
  • For physicians, this data can inform more thoughtful prescribing.
  • For researchers, this information will reinforce continued investigation into more effective forms of available symptomatic therapies, like levodopa, and into curative therapies.

https://www.michaeljfox.org/foundation/news-detail.php?new-study-urges-stronger-warning-for-parkinson-medications-tied-to-impulsive-behaviors

My Challenges with REM Sleep and Parkinson’s Disease

FoxFeed Blog

Posted by  John Cobb, October 24, 2014
The author up reading in the middle of the night.
The author up reading in the middle of the night.
John Cobb was diagnosed with Parkinson's in August 2011. He is a retired pharmacist, a husband, a father and a grandfather. He blogs at Personal Parkinson's.
There is a certain clarity that comes with rising in the small hours of the night. The hours when the silence is broken only by sound of your spouse breathing or the movement of yellow dog Bella as she turns over in a dog's blissful dreams. I creep out of bed and position myself in the stuffed chair next to Bella. I open my iPad and begin to think about why I am awake at this time when most people are asleep. 
I am awake because this is one more piece of this puzzle known as Parkinson’s. Since the earliest days of Parkinson's disease (PD) I have awakened around 1:30 or 2 a.m., often unable to return to sleep. Frequently I wake up in the midst of a stage of sleep known as REM sleep, that period of sleep when your eyes move rapidly and dreaming occurs. In this stage the brain somehow finds rest while it links confusing pieces of information into a story of sorts. These dreams have been especially vivid for me and I sometimes wake up when I am acting out some portion of the dream.
One night I found myself being pursued and desperately trying to escape the pack competitors in a roller derby. I woke trying to hold back the pursuing pack on roller skates by slugging away with an elbow. Strangely I am neither a fan nor have ever had anything to do with roller derby. They say that usually the brain has a barrier that wakes us up prior to becoming physically engaged with a dream. In Parkinson's that barrier has been removed or at least messed with and so I have reached, kicked or slugged as a dream is happening.
Our patterns of sleep may modified by Parkinson's itself or by drugs intended for the purpose of inducing sleep. Changes may also be due to side effects of a drug never intended to influence sleep. For myself this is likely the case and it began a few months ago when I added a drug called Artane for tremors. For tremors it was and is helpful, but without explanation, both the early awakening and the vivid dreams stopped. I assumed that the better night's sleep was due to the addition of Artane since I knew that Artane could cause drowsiness and thereby assist sleep. Nice! But I also was puzzled by the disappearance of my vivid dreams or any dreams. 
I found among the list of side effects that Artane not only causes drowsiness but also suppresses REM sleep. REM sleep is quite important to achieving the natural restorative sleep the body needs. More sleep but lower quality of sleep has been a concern with sleeping pills for a long time. Now on Artane I sleep longer but seem to be nearly or as tired as when I woke early every day. 
There is little doubt that Artane has been very helpful for tremors but hidden among the side effects there is a price to be paid. It would seem that more sleep also means lower quality of sleep.
https://www.michaeljfox.org/foundation/news-detail.php?my-challenges-with-rem-sleep-and-parkinson-disease